# Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

> **NCT01087762** · PHASE3 · COMPLETED · sponsor: **UCB BIOSCIENCES GmbH** · enrollment: 325 (actual)

## Conditions studied

- Spondyloarthropathies

## Interventions

- **BIOLOGICAL:** CZP 200 mg Q2W
- **BIOLOGICAL:** CZP 400 mg Q4W
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01087762
- **Lead sponsor:** UCB BIOSCIENCES GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-10
- **Final completion:** 2015-08
- **Target enrollment:** 325 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01087762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01087762, "Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01087762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*